GPCRs

InterAx Biotech AG is strengthening its scientific advisory board

Scientific advisory boards set the bar for the quality of research and development performed in big pharma, medium biotech and small start-ups. Their excellence...

More details More details

InterAx Biotech has started a new collaboration

Collaborations speed up innovation. InterAx Biotech AG, a spin-off of the Paul Scherrer Institute (PSI) and ETH Zurich, based at PARK INNOVAARE, and Professor...

More details

Shaping the future of modern drug discovery

Video interview with Professor Dr. Gebhard Schertler Pharmaceutical and biotechnological industries often depend on the information acquired through...

More details

The value of the absolute structure

The exact knowledge and understanding of a molecule’s structure underpin all the substantial progress in chemical, agrarian and pharmaceutical research....

More details

Unprecedented speed and success rate with delivering ligand-bound GPCR structures

Modern drug discovery greatly benefits from knowledge of how a drug interacts with its molecular drug target. Membrane protein drug targets represent a...

More details

State-of-the-art bioinformatics for better drug discovery

The effect a drug has on the human body depends on how well its active substance find its way to the targeted cells in the body, and on the chemical reactions...

More details

Biosensors Technology Platform for efficient lead discovery

In April 2016, the team at InterAx Biotech AG mounted the nameplate of a newly-born company on the wall of PARK INNOVAARE’s deliveryLAB, thus giving...

More details
Subscribe to GPCRs